Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
about
Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysisManagement of diabetes in the elderly with canagliflozin: A newer hypoglycemic drug on the horizonTreating the elderly diabetic patient: special considerationsHighlights Regarding Host Predisposing Factors to Recurrent Vulvovaginal Candidiasis: Chronic Stress and Reduced Antioxidant CapacityThe role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.Sodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trialsOptimal therapy of type 2 diabetes: a controversial challengeEmerging treatments in type 2 diabetes: focus on canagliflozin.Genital mycotic infections in patients with diabetes.Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetesCanagliflozin: effects in overweight and obese subjects without diabetes mellitus.Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trialsEfficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study.The role of empagliflozin in the management of type 2 diabetes by patient profile.Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetesSGLT-2 Inhibitors: A New Mechanism for Glycemic Control.Update on Safety Issues Related to Antihyperglycemic TherapyEfficacy and safety of canagliflozin in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.Canagliflozin.Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapyEstrogen treatment predisposes to severe and persistent vaginal candidiasis in diabetic mice.The renal effects of SGLT2 inhibitors and a mini-review of the literature.Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetesDifferentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes.Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.Successful integration of nonclinical and clinical findings in interpreting the clinical relevance of rodent neoplasia with a new chemical entity.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes.
P2860
Q26773558-CB1A92FB-853F-4880-A02D-8D7B1922EBACQ26827362-8A7C3805-E434-4ECF-ACD9-247596B8C81CQ26995176-4E10C37A-9F85-44B4-8F77-FCA5511501B4Q28552602-B23D122C-C3B7-43D5-8D94-6D096B4E272AQ30663494-FB0F950F-DA53-4B9C-A253-BEC6AD103CBDQ30833760-5E7C1783-BE34-4E57-937F-0DE04E636AA6Q33567077-26ADD97F-B0A9-4ED5-AD0A-68CA14FBE251Q33577712-D357BE67-2372-4B9B-B35E-06938F76D133Q34109789-6FE6DB05-91DE-48F9-8B79-6D87FFD6B0A7Q34349532-885BF317-D1F3-4941-8FB1-38145617A528Q34646948-EFE62BD1-7841-4D9B-89A5-2585CEEB1DCEQ34699217-669696B3-C05B-4F03-AB10-8B6282F61A60Q34851219-443C5320-015D-498A-8A5E-B530731BCE83Q35068181-6A064A4E-7355-4622-9D88-65EAD3D6F263Q35192198-9BB2EBB7-3DA1-4DA4-AD1D-207A0E57AB3CQ35592873-FCF42A8D-80B5-4BE9-965E-010988644366Q35780861-EB832FAA-813D-4D08-A062-AE921C4FFDD1Q35906490-206D6FDC-A37B-46DA-991F-5A836853688FQ35910429-33B30190-8876-47D9-9477-9CDB5FB2463BQ36207940-3956B2AF-615A-441E-8EE8-5A3651A62960Q37060855-F297CCC4-0772-4572-BCC5-FBB327D18B54Q37279276-864D8C3B-D56E-4032-ACB7-29F3B64E77F4Q37383648-FBCA38BA-FFEA-43C8-95FD-25DFBCF786B4Q37461695-3C627899-A215-454B-86DA-9D38076360F0Q37562111-0B1E8586-C58D-4870-9FA2-7C0A2E95DE75Q37632127-6B513C2F-8C47-4A42-9091-8635742BEC9DQ37653114-8C779D38-9F35-4B8F-B2F1-CF15F73303F9Q37661798-ADCBE33F-9DDD-44ED-B159-6632799F8336Q37741752-B0E34D26-DBD0-49FB-A4A9-418A2390AF91Q38085691-149A6FC8-94C6-40D4-9B20-F7D0BBF8C454Q38130748-9A205DF7-EF18-4F52-A699-E6C17985CD00Q38164682-52586A5B-8896-4890-B3DD-C0DF34CB57F6Q38175467-82A5ED3A-799F-434A-9078-99BC1ABF7E10Q38176145-0A2934AA-8E91-4D06-8BC6-E0E8DAC8DD18Q38211881-55E16CDA-952C-4331-9B71-9744F3513C51Q38212007-610FBFE8-AA08-4364-8251-232477693609Q38340949-EEA4F697-E461-4F1C-8E0A-8415851E392EQ38562860-60282AC8-951F-4A45-AB87-7029FAA13002Q38619164-3849894B-F634-4C1C-89F1-FD1A3311432BQ38777020-CF61DD26-9CA7-4E1F-8082-1F7359EF84A6
P2860
Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Evaluation of vulvovaginal sym ...... se co-transporter 2 inhibitor.
@en
Evaluation of vulvovaginal sym ...... se co-transporter 2 inhibitor.
@nl
type
label
Evaluation of vulvovaginal sym ...... se co-transporter 2 inhibitor.
@en
Evaluation of vulvovaginal sym ...... se co-transporter 2 inhibitor.
@nl
prefLabel
Evaluation of vulvovaginal sym ...... se co-transporter 2 inhibitor.
@en
Evaluation of vulvovaginal sym ...... se co-transporter 2 inhibitor.
@nl
P2093
P921
P1476
Evaluation of vulvovaginal sym ...... se co-transporter 2 inhibitor.
@en
P2093
Keith Usiskin
Paul Nyirjesy
P304
P356
10.1185/03007995.2012.697053
P407
P577
2012-06-14T00:00:00Z